Showing results (261-270 of 342) with videos related to
Sort By:
Pageof 35
Australian Health Review : a Publication of the Australian Hospital Association|December 1, 2011
A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatmentSenthil Lingaratnam, Leon J Worth, Monica A Slavin, et al.Blood|July 20, 2002
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemiaNorbert Schmitz, Meral Beksac, Dirk Hasenclever, et al.British Journal of Haematology|May 26, 2020
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studiesRégis Peffault de Latour, Robert A Brodsky, Stephan Ortiz, et al.Transplantation and Cellular Therapy|March 30, 2021
Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow TransplantationNina Worel, Bronwen E Shaw, Mahmoud Aljurf, et al.Leukemia & Lymphoma|May 22, 2014
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trialJason D Lickliter, Kerry Taylor, Jeff Szer, et al.Orphanet Journal of Rare Diseases|January 7, 2022
Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trialsDeborah Elstein, Nadia Belmatoug, Patrick Deegan, et al.The Lancet. Haematology|February 2, 2019
Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 studyNoelle Frey, Jun Ho Jang, Jeff Szer, et al.Arthritis and Rheumatism|October 2, 2002
A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritisJohn Moore, Peter Brooks, Sam Milliken, et al.Journal of Clinical Medicine|June 27, 2024
Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient RegistryDeborah Elstein, Nadia Belmatoug, Bruno Bembi, et al.Orphanet Journal of Rare Diseases|September 28, 2013
Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher diseaseYildiz Yildiz, Per Hoffmann, Stefan Vom Dahl, et al.Pageof 35